Predictmedix AI Unveils Cutting-Edge Contactless Integrative AI Solutions for Healthcare in India and Incorporates Fully Owned Indian Subsidiary

Toronto, Ontario - July 19, 2023– Predictmedix AI Inc. (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) (the "**Company**" or "**Predictmedix**") is proud to announce its ground-breaking contactless integrative AI solutions for healthcare, poised to revolutionize the industry in India. Leveraging the power of advanced AI algorithms and state-of-the-art technology, Predictmedix aims to enhance the efficiency, accuracy, and safety of healthcare practices across the country.

A report on the National Strategy for Artificial Intelligence by the NITI Aayog showed that shortage of qualified healthcare professionals and non-uniform accessibility to healthcare across the country prevails. India has only 64 doctors available per 100,000 people compared to the global average of 150. This significant disparity highlights the urgent need for innovative solutions to bridge the healthcare gap and improve healthcare outcomes for the Indian population.[1]

With the growing demand for innovative healthcare solutions, Predictmedix is at the forefront of developing advanced AI-powered tools designed to transform the way medical professionals provide care. By eliminating the need for physical contact, these cutting-edge solutions address the challenges and contribute to the overall improvement of healthcare delivery.

Predictmedix's contactless integrative AI solutions combine computer vision, thermal imaging, and predictive analytics to enable seamless and efficient healthcare interactions. These solutions offer a range of capabilities, including contactless temperature screening, symptom analysis, mental health assessments, and substance abuse detection, among others. By employing sophisticated algorithms, Predictmedix ensures accurate and reliable results, empowering healthcare providers with valuable insights to make informed decisions.

"We are thrilled to introduce our contactless integrative AI solutions to the Indian healthcare landscape," said Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix. "Our technology represents a significant leap forward in medical diagnostics and screening. By minimizing physical contact, we are prioritizing patient safety while maximizing the

efficiency and effectiveness of healthcare practices."

Aligned with the vision of the Atmanirbhar Bharat Digital Mission (ABDM), Predictmedix's contactless integrative AI solutions exemplify India's commitment to harnessing cutting-edge technology to address critical healthcare challenges. ABDM, initiated by the Government of India, seeks to empower citizens with digital services and solutions while fostering self-reliance in the digital domain. [2]

Predictmedix's AI solutions have already garnered recognition and adoption globally, earning accolades for their potential to reshape healthcare systems. With the launch of these innovative offerings in India, Predictmedix aims to collaborate with healthcare providers, government institutions, and industry stakeholders to drive positive change and improve healthcare outcomes for the nation's population. To expedite collaborations and business development in India, Predictmedix is incorporating a fully owned Indian subsidiary and has received approval from the government for the subsidiary to be called "Predictmedix India Pvt Ltd".

By leveraging AI and advanced technology, Predictmedix empowers healthcare professionals to proactively identify potential health risks, expedite diagnosis, and enhance patient care. The company's commitment to research and development ensures continuous innovation and the development of future-proof solutions that adapt to the evolving needs of the healthcare industry.

1 https://www.thehindu.com/brandhub/integrating-ai-into-healthcare-a-trillion-dollar-opportunity-for-india/article66060253.ece/amp/

2 https://interestingengineering.com/health/india-gives-14-billion-people-healthcare

About Predictmedix AI Inc.

Predictmedix AI Inc. (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedi AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.

Public Relations Contact

For further media information or to set up an interview, please contact:

Nelson Hudes Hudes

Communications International (905) 660 9155

Nelson@hudescommunications.com

Dr. Rahul Kushwah (647) 889 6916

Caution Regarding Forward-Looking Information:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking

information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.